Literature DB >> 17575148

Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma.

Richard Morgan1, Patricia Macanas Pirard, Liesl Shears, Jastinder Sohal, Ruth Pettengell, Hardev S Pandha.   

Abstract

Malignant melanoma is a cancer that arises from melanocyte cells in a complex but well-studied process, and which can only be successfully treated prior to metastasis as it is highly resistant to conventional therapies. A number of recent reports have indicated that members of the HOX family of homeodomain-containing transcription factors are deregulated in melanoma, and may actually be required to maintain proliferation. In this report, we describe the use of a novel, cell-permeable antagonist of the interaction between HOX proteins and PBX, a second homeodomain-containing transcription factor that modifies HOX activity. This antagonist can block the growth of murine B16 cells and trigger apoptosis both in vitro and in vivo when administered to mice with flank tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575148     DOI: 10.1158/0008-5472.CAN-06-4231

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

Authors:  Zejuan Li; Hao Huang; Yuanyuan Li; Xi Jiang; Ping Chen; Stephen Arnovitz; Michael D Radmacher; Kati Maharry; Abdel Elkahloun; Xinan Yang; Chunjiang He; Miao He; Zhiyu Zhang; Konstanze Dohner; Mary Beth Neilly; Colles Price; Yves A Lussier; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Lars Bullinger; Peter J M Valk; Ruud Delwel; Bob Lowenberg; Paul P Liu; Guido Marcucci; Clara D Bloomfield; Janet D Rowley; Jianjun Chen
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

2.  Structural basis for homeodomain recognition by the cell-cycle regulator Geminin.

Authors:  Bo Zhou; Changdong Liu; Zhiwen Xu; Guang Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 3.  The Hox genes and their roles in oncogenesis.

Authors:  Nilay Shah; Saraswati Sukumar
Journal:  Nat Rev Cancer       Date:  2010-04-01       Impact factor: 60.716

Review 4.  Transcription factor-mediated reprogramming toward hematopoietic stem cells.

Authors:  Wataru Ebina; Derrick J Rossi
Journal:  EMBO J       Date:  2015-02-20       Impact factor: 11.598

Review 5.  Multiple roles of HOX proteins in Metastasis: Let me count the ways.

Authors:  Joy Jonkers; Priya Pai; Saraswati Sukumar
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 6.  Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets.

Authors:  C T Collins; J L Hess
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

7.  Targeting HOX and PBX transcription factors in ovarian cancer.

Authors:  Richard Morgan; Lynn Plowright; Kevin J Harrington; Agnieszka Michael; Hardev S Pandha
Journal:  BMC Cancer       Date:  2010-03-10       Impact factor: 4.430

8.  Expressional profiles of transcription factors in the progression of Helicobacter pylori-associated gastric carcinoma based on protein/DNA array analysis.

Authors:  Ting-Zi Hu; Li-Hua Huang; Can-Xia Xu; Xiao-Ming Liu; Yu Wang; Jing Xiao; Li Zhou; Ling Luo; Xiao-Xia Jiang
Journal:  Med Oncol       Date:  2015-11-12       Impact factor: 3.064

9.  HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer).

Authors:  L Plowright; K J Harrington; H S Pandha; R Morgan
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

10.  Unique molecular characteristics of pediatric myxopapillary ependymoma.

Authors:  Valerie N Barton; Andrew M Donson; Bette K Kleinschmidt-DeMasters; Diane K Birks; Michael H Handler; Nicholas K Foreman
Journal:  Brain Pathol       Date:  2009-09-10       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.